Immune checkpoint inhibitors and cardiovascular toxicity
Open Access
- 1 September 2018
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 19 (9) , e447-e458
Abstract
No abstract availableKeywords
Funding Information
- NIHR Cambridge Biomedical Research Centre
This publication has 56 references indexed in Scilit:
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaBlood, 2013
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesEuropean Heart Journal, 2013
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Mechanistic links between acute respiratory tract infections and acute coronary syndromesJournal of Infection, 2013
- Immunotherapies for non-small-cell lung cancer and mesotheliomaThe Lancet Oncology, 2012
- PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated MyocarditisThe Journal of Immunology, 2012
- Stress (Takotsubo) cardiomyopathy—a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunningNature Clinical Practice Cardiovascular Medicine, 2008
- CTLA-4 Ablation and Interleukin-12–Driven Differentiation Synergistically Augment Cardiac Pathogenicity of Cytotoxic T LymphocytesCirculation Research, 2007
- Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient miceNature Medicine, 2003
- Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient MiceScience, 2001